We are testing the overarching hypothesis that the induction and activation of tumor-residing cDC1s would facilitate the priming, expansion, and infiltration of tumor-specific CD8+ T cells into the poorly T cell-inflamed TME, and overcome resistance to anti-PD-L1 therapy. The gene discussed is CD8A; the disease is neoplasm.